MissionIR would like to highlight
International Stem Cell Corporation (
OTCBB: ISCO), researching the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). The company is focused on using these stem cells to treat diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells or tissue.
In the company’s news:
In a recent article on the Jewish Journal website (http://dtn.fm/DhxK8), doctors, dignitaries and officials representing Israel and California convened at Cedars-Sinai Medical Center on February 8, 2016, to witness the signing of an agreement between Israel’s Ministry of Science and the California Institute for Regenerative Medicine (CIRM) to collaborate on stem cell research. It follows a 2014 Memorandum of Understanding to promote collaboration and innovation between Israel and California.
“Stem cell research is a cutting-edge field full of promise and opportunity. Who better to forge new ground together than the State of Israel and the State of California?” Israeli Minister of Science, Technology and Space Ofir Akunis said in the article. “Both are hotbeds of innovation, medical research and technological invention and have a strong commitment to science as a means to improve the lot of all humanity … creating a brighter future for us all.”
International Stem Cell Corp. (OTCQB: ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. The company’s stem cells present superior immune matching capabilities and can be used in millions of people, regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
Stem cells are the future of medicine. Companies like International Stem Cell Corp. are on the front lines of this invaluable research, constantly looking for new ways stem cells can improve our quality of life by treating and eliminating diseases of the central nervous system (i.e. Parkinson’s disease), the liver, and the eye. The technology is getting better every day, and more people are coming around to at least giving it a look. The company has an ethical and moral purpose along with the potential to capitalize on a huge revenue stream.
The combined direct and indirect costs of Parkinson’s disease (PD), including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the U.S. alone. Medication costs for an individual person with PD average $2,500 a year, and therapeutic surgery can cost up to $100,000 dollars per patient.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
